Filing Analysis
Tenaya Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings press release issued on August 5, 2026.
📋 Key Facts
- Report date: August 5, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes an Earnings Press Release as Exhibit 99.1
- Company is classified as an emerging growth company
Tenaya Therapeutics has entered into a lease termination agreement for its Genetic Medicines Manufacturing Center (GMMC Facility) in Union City, CA. The facility was previously decommissioned in 2025 as part of cost-reduction efforts.
🚩 Red Flags
- Forfeiture of $1.75M security deposit represents a significant cash/asset loss
📋 Key Facts
- Lease termination date: August 31, 2026
- Facility size: Approximately 94,046 rentable square feet
- Termination consideration: Forfeiture of $1,750,000 security deposit and a one-time fee of ~$294,200
- Original lease expiration was scheduled for July 2031
- Company plans to transition AAV manufacturing to a CDMO (Contract Development Manufacturing Organization)
Tenaya Therapeutics announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 13, 2026. He will also assume roles as Principal Financial Officer and Principal Accounting Officer, replacing interim leadership.
📋 Key Facts
- Eric Hyllengren to join as CFO on July 13, 2026.
- Hyllengren will serve as Principal Financial Officer (PFO) and Principal Accounting Officer (PAO).
- Annual base salary is set at $490,000 with a target annual bonus of 40% of base salary.
- The offer includes an option to purchase 1,650,000 shares of common stock under the 2024 Inducement Equity Incentive Plan.
- Interim PFO Faraz Ali and acting interim PAO Tomohiro Higa will cease their respective roles effective prior to Hyllengren's commencement.
Tenaya Therapeutics reported the results of its May 27, 2026, annual meeting of stockholders. The company successfully elected Class II directors, ratified Deloitte & Touche LLP as its auditor, and approved an amended and restated 2021 Equity Incentive Plan.
🚩 Red Flags
- The approval of the Equity Incentive Plan (Proposal 3) saw a notable amount of 'Against' votes (20,575,701) compared to the 'For' votes (67,356,607), indicating some shareholder resistance to the dilution.
📋 Key Facts
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan on May 27, 2026.
- The incentive plan update includes a one-time increase of 6,509,966 shares (approx. 3% of outstanding shares).
- The 'evergreen' provision was amended to remove the 4 million share annual limit, keeping the increase at 4% of outstanding shares.
- Class II Directors Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen were elected to serve until 2029.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Tenaya Therapeutics announced its financial results for the first quarter ended March 31, 2026. The filing is a routine disclosure of quarterly performance and includes the earnings press release as an exhibit.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- Filing dated May 6, 2026
- Triggered Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release
Tenaya Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal announcement of these results via a press release attached as Exhibit 99.1.
📋 Key Facts
- The report was filed on March 11, 2026.
- The financial results cover the fiscal quarter and full year ended December 31, 2025.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- The company is classified as an emerging growth company.
Tenaya Therapeutics entered into a multi-target research collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for cardiovascular disease. The deal includes an upfront payment of up to $10 million and potential future milestones totaling $1.13 billion.
🚩 Red Flags
- Alnylam may unilaterally terminate the agreement in its entirety for any or no reason.
- The upfront payment is relatively small ($10M) compared to the $1.13B headline milestone figure, which is highly contingent on long-term success.
📋 Key Facts
- Agreement signed on March 4, 2026, for a 24-month initial research collaboration period.
- Tenaya and Alnylam will nominate an aggregate of 15 targets for validation.
- Tenaya receives an upfront payment of up to $10.0 million, subject to $500,000 reductions for certain targets not advanced.
- Tenaya is eligible for up to $1.13 billion in aggregate development, regulatory, and sales-based milestones.
- Alnylam will reimburse Tenaya for full-time employees (FTEs) and out-of-pocket costs during the validation phase.
- Alnylam assumes sole responsibility for development, manufacturing, and commercialization after the validation phase.
Tenaya Therapeutics received a notice from Nasdaq indicating the company failed to meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The company has been granted a 180-day compliance period ending July 27, 2026.
🚩 Red Flags
- Delisting notice: Failure to meet minimum bid price requirement ($1.00).
- Potential for a reverse stock split to regain compliance.
- Risk of transfer from Nasdaq Global Select Market to Nasdaq Capital Market.
📋 Key Facts
- Nasdaq deficiency period: December 12, 2025, through January 27, 2026.
- Compliance deadline: July 27, 2026 (180-day window).
- Requirement to regain compliance: Maintain a closing bid price of at least $1.00 for 10 consecutive business days.
- Potential secondary compliance period: Possible transfer to Nasdaq Capital Market if the company effects a reverse stock split and meets other criteria.
- The Board approved an amendment to the 2024 Inducement Equity Incentive Plan, increasing reserved shares by 2,161,000 (totaling 3,361,000).
Tenaya Therapeutics announced the voluntary resignation of Director David Goeddel from the Board and all committees. The departure is due to his retirement and is effective January 26, 2026.
📋 Key Facts
- Director David Goeddel submitted his resignation on December 31, 2025.
- The resignation is voluntary and related to his retirement.
- Effective date of departure from the Board and all committees is January 26, 2026.
- The Company explicitly stated there was no disagreement with management regarding operations, policies, or practices.
Tenaya Therapeutics announced a firm commitment underwriting agreement to conduct a public offering of 50 million units at $1.20 per unit, expected to raise approximately $60 million in gross proceeds. The units consist of one share of common stock and one warrant with an exercise price of $1.50.
🚩 Red Flags
- Significant dilution: Issuance of 50 million new shares plus warrants will significantly dilute existing shareholders.
- Warrant overhang: The issuance of 50 million warrants at a $1.50 exercise price creates potential future dilution and downward pressure on the stock price.
📋 Key Facts
- Offering size: 50,000,000 units
- Price per unit: $1.20 (consisting of 1 share + 1 warrant)
- Expected gross proceeds: ~$60 million
- Underwriters: Leerink Partners LLC and Piper Sandler & Co.
- Warrant terms: Exercise price of $1.50, exercisable for five years
- Closing date: Expected December 15, 2025
- Lock-up period: 60 days for company officers, directors, and certain holders
Tenaya Therapeutics announced the FDA has removed the clinical hold on its MyPEAK-1 trial for TN-201 and provided positive interim data from its RIDGE-1 trial for TN-401. The company expects to present further clinical data in the first half of 2026.
🚩 Red Flags
- Previous clinical hold on MyPEAK-1 trial (resolved).
- One instance of Grade 1 elevated troponin levels categorized as a serious AE due to inpatient monitoring.
- Confounding result in Patient 3 where PKP2 protein levels appeared lower than baseline despite high mRNA expression.
📋 Key Facts
- FDA removed the clinical hold on the MyPEAK-1 clinical trial (TN-201) as of December 11, 2025.
- The clinical hold was due to a request for protocol amendments regarding patient monitoring and immunosuppression management.
- Interim data from RIDGE-1 (TN-401) Cohort 1 showed TN-401 was generally well tolerated with no dose-limiting toxicities.
- Two of three patients in RIDGE-1 Cohort 1 showed significant reductions in premature ventricular contractions (PVCs): Patient 1 by 46% and Patient 2 by 89%.
- TN-401 demonstrated robust mRNA expression and increased PKP2 protein levels in two of the three patients.
- Company expects to present one-year Cohort 1 and early Cohort 2 data for RIDGE-1 in H1 2026.
Tenaya Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2025. The filing serves as a formal notice of the release of the company's earnings press release.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes an Earnings Press Release as Exhibit 99.1
- Company is classified as an emerging growth company
The FDA has placed a clinical hold on Tenaya Therapeutics' Phase 1b/2a MyPEAK-1 trial for TN-201. The hold is related to requested protocol amendments regarding patient monitoring and immunosuppression management rather than new safety concerns.
🚩 Red Flags
- FDA clinical hold on a primary drug candidate (TN-201) is a significant regulatory setback for a biotech firm.
- Potential for delays in clinical data readout, despite management's optimistic outlook.
📋 Key Facts
- FDA issued a clinical hold on the MyPEAK-1 clinical trial evaluating TN-201 (for MYBPC3-associated hypertrophic cardiomyopathy).
- The hold is due to requested amendments to standardize patient monitoring and immunosuppression management across sites.
- A Summer 2025 DSMB review previously concluded TN-201 had an acceptable safety profile for expansion cohorts at 3E13 vg/kg or 6E13 vg/kg doses.
- Tenaya reports no new meaningful safety events since the DSMB review.
- The company expects to resume dosing once protocol changes are implemented and does not anticipate impact on data milestones or development timelines.
Tenaya Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal announcement of the earnings press release issued on August 6, 2025.
📋 Key Facts
- Company announced financial results for the quarter ended June 30, 2025.
- The announcement was made via an Earnings Press Release dated August 6, 2025.
- The filing includes Exhibit 99.1 containing the full text of the press release.
Tenaya Therapeutics held its annual meeting of stockholders on May 28, 2025. The filing reports the successful election of three Class I Directors and the ratification of Deloitte & Touche LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on May 28, 2025.
- Three Class I Directors elected: David Goeddel, Ph.D., Jeffrey T. Walsh, M.B.A., and R. Sanders Williams, M.D.
- Directors to serve until the 2028 annual meeting of stockholders.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Tenaya Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the release of their quarterly earnings press release.
📋 Key Facts
- Report date: May 7, 2025
- Reporting period: Quarter ended March 31, 2025
- The company issued an Earnings Press Release as Exhibit 99.1
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition)
Tenaya Therapeutics received a notice from Nasdaq indicating the company failed to meet the minimum $1.00 bid price requirement over a 30-day period ending April 12, 2025. The company has been granted a 180-day compliance period until October 13, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq due to minimum bid price deficiency.
- Explicit mention of potential necessity for a reverse stock split to meet listing requirements in the second compliance period.
- Risk of being unable to qualify for additional cure periods if Nasdaq determines compliance is unlikely.
📋 Key Facts
- Nasdaq deficiency period: March 3, 2025, through April 12, 2025.
- Compliance deadline: October 13, 2025 (180-day window).
- Requirement to regain compliance: Maintain a closing bid price of at least $1.00 for 10 consecutive business days.
- Potential secondary recourse: A second 180-day period may be available via transfer to the Nasdaq Capital Market, which would likely require a reverse stock split.
Tenaya Therapeutics has announced a restructuring plan involving workforce reductions to focus resources on its core gene therapy programs (TN-201 and TN-401). The move is intended to extend the company's cash runway into the second half of 2026 through significant cost containment.
🚩 Red Flags
- Workforce reduction indicates significant cost-cutting measures and resource constraints.
- Cash runway is limited, extending only into H2 2026, highlighting a dependency on future funding or clinical milestones.
- Restructuring charges of up to $2.7 million impact near-term earnings.
📋 Key Facts
- Restructuring plan approved on March 27, 2025.
- Workforce reduction implemented to align with business focus on MyPEAK-1 and RIDGE-1 programs.
- Estimated restructuring charges of $1.6 million to $2.7 million, primarily for severance and health benefits.
- Expected extension of cash runway into the second half of 2026.
- All charges expected to be recognized by the end of Q3 2025.
Tenaya Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly and annual earnings results.
- Report date: March 10, 2025.
- Reporting period covered: Quarter and Year ended December 31, 2024.
- The company is classified as an 'emerging growth company'.
Tenaya Therapeutics announced a large-scale public offering of 75 million units at $0.70 per unit, expected to raise approximately $52.5 million in gross proceeds. The offering includes common stock and two series of warrants (Series A and Series B).
🚩 Red Flags
- Significant dilution potential due to the issuance of 75 million new shares and accompanying warrants.
- Warrant pricing ($0.70 - $0.80) is at or near the offering price, suggesting a highly dilutive structure common in distressed or high-growth biotech financing.
- Suspension of existing ATM prospectus suggests a shift toward more structured/dilutive capital raising needs.
📋 Key Facts
- Offering size: 75,000,000 units.
- Price per unit: $0.70.
- Expected gross proceeds: ~$52.5 million.
- Units consist of one share of common stock, one Series A Warrant (exercise price $0.80, 5-year term), and one Series B Warrant (exercise price $0.70, expires June 30, 2026).
- Underwriters: Leerink Partners LLC and Piper Sandler & Co.
- Expected closing date: March 5, 2025.
- The company has suspended its existing At-the-Market (ATM) prospectus.
Tenaya Therapeutics announced the appointment of Tomohiro Higa as Interim Principal Accounting Officer and disclosed a significant stock option repricing for CEO Faraz Ali. The repricing aims to retain the CEO by lowering exercise prices from a range of $5.64–$15.19 down to $1.21 per share.
🚩 Red Flags
- Significant option repricing for the CEO (related-party transaction) suggests substantial portion of equity is 'underwater'.
- Appointment of an 'Interim' Principal Accounting Officer may indicate recent turnover or vacancy in the finance leadership role.
- The repricing was necessitated by a significant decline in stock price, as original prices were up to $15.19 while new price is $1.21.
📋 Key Facts
- Tomohiro Higa appointed as Interim Principal Accounting Officer effective February 6, 2025.
- CEO Faraz Ali granted an option repricing for approximately 915,875 shares.
- Repriced options exercise price set at $1.21 per share (the higher of the current closing price or the Jan 24 repricing price).
- Original exercise prices for CEO's eligible options ranged from $5.64 to $15.19.
- Repricing includes a 'Retention Goal Achievement' clause requiring the CEO to remain with the company through July 24, 2025, or until a Change in Control.
Tenaya Therapeutics announced an option repricing effective January 24, 2025, for nonstatutory stock options held by employees that were 'underwater'. The new exercise price is set at $1.21 per share, which was the closing price on the effective date.
🚩 Red Flags
- Significant portion of equity is 'underwater' (exercise prices significantly above market price).
- Option repricing for insiders/officers (CMO Whit Tingley) can be viewed as a dilution-avoidance mechanism that favors management at the expense of existing shareholders.
- The company admits a substantial majority of employee stock options were underwater.
📋 Key Facts
- Effective Date: January 24, 2025
- New Exercise Price: $1.21 per share (previously ranging from $3.06 to $21.01)
- Total shares underlying repriced options: approximately 4,133,517 shares
- Repricing includes options held by Chief Medical Officer Whit Tingley (630,982 shares) with original prices between $3.06 and $15.19
- Retention requirement: Holders must remain a service provider through July 24, 2025 ('Retention Date') to benefit from the lower price; otherwise, they pay the original higher exercise price if exercised early.
Tenaya Therapeutics announced early clinical data from the first cohort of its MyPEAK-1 Phase 1b/2 trial for TN-201, a gene therapy for hypertrophic cardiomyopathy (HCM). The data indicates that the therapy was generally well tolerated and showed evidence of successful transgene expression in patients.
🚩 Red Flags
- All three patients experienced isolated elevations in liver enzymes (a known side effect of AAV therapies).
- One patient required a corticosteroid bolus in the hospital setting due to enzyme elevation, resulting in an SAE designation for that specific administration event.
📋 Key Facts
- Early data from three patients in the first dose cohort (3E13 vg/kg) of the MyPEAK-1 trial for TN-201.
- TN-201 was generally well tolerated; no cardiac toxicities or TMA-related events were observed.
- Observed isolated elevations in liver enzymes in all three patients, managed with corticosteroids.
- Biopsy data from Patients 1 and 2 showed robust cardiac transduction and increased TN-201 mRNA expression (50% increase at Week 52 for Patient 1).
- MyBP-C protein levels demonstrated a 3% increase from Weeks 8 to 52 in Patient 1.
- Clinical markers like NT-proBNP remained stable, and Cardiac troponin I normalized in Patient 2.
Tenaya Therapeutics announced the resignation of Chihiro Saito from her dual roles as Senior Vice President, Accounting and Financial Operations and Interim Principal Accounting Officer, effective December 16, 2024.
🚩 Red Flags
- Departure of an Interim Principal Accounting Officer (PAO) can create temporary gaps in financial oversight and reporting stability.
📋 Key Facts
- Chihiro Saito resigned as SVP, AFO and Interim PAO on December 16, 2024.
- The resignation was to pursue another opportunity.
- The company explicitly stated the resignation is not due to any disagreement regarding financials, operations, policies, or practices.
Tenaya Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal announcement of the release of their quarterly earnings press release.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Quarter ended September 30, 2024
- The company issued an Earnings Press Release as Exhibit 99.1
- Information provided under Item 2.02 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Tenaya Therapeutics announced a board reclassification to balance director classes and the adoption of a new 2024 Inducement Equity Incentive Plan. The filing also notes the previous resignation of Jin-Long Chen.
🚩 Red Flags
- Board size reduction (from previous larger structure to 9 directors).
📋 Key Facts
- Karah Parschauer reclassified from Class I to Class II director, effective September 12, 2024.
- The Board size was reduced to a total of nine authorized directors (three in each class).
- Adopted the '2024 Inducement Equity Incentive Plan' on September 12, 2024.
- Reserved 1,200,000 shares of common stock for issuance under the new Inducement Plan.
- The Inducement Plan was adopted without stockholder approval per Nasdaq Listing Rules.
Tenaya Therapeutics announced the departure of its Chief Financial and Business Officer, Ms. Leone Patterson, effective August 14, 2024. The company has appointed interim leadership to fill the Principal Financial Officer (PFO) and Principal Accounting Officer (PAO) roles.
🚩 Red Flags
- Departure of the CFO/Business Officer and both Principal Financial/Accounting Officers simultaneously creates a leadership vacuum in finance.
- CEO assuming PFO duties is a sign of internal resource constraints or sudden transition.
📋 Key Facts
- Leone Patterson is ceasing her role as Chief Financial and Business Officer, PFO, and PAO on August 14, 2024.
- CEO Faraz Ali will assume the role of Interim Principal Financial Officer (PFO) effective August 14, 2024.
- Chihiro Saito, SVP of Accounting and Financial Operations, will assume the role of Interim Principal Accounting Officer (PAO) effective August 14, 2024.
- The company also issued its Q2 2024 financial results press release on August 8, 2024.
Tenaya Therapeutics announced the resignation of its Chief Financial and Business Officer (CFBO), Leone Patterson, effective August 14, 2024. The departure is reportedly to pursue another opportunity and not due to any disagreements regarding company financials or operations.
🚩 Red Flags
- Departure of key executive (CFBO/Principal Accounting Officer) during a critical period for biotech companies.
📋 Key Facts
- Leone Patterson resigned from her roles as CFBO, Principal Financial Officer, and Principal Accounting Officer on July 19, 2024.
- The resignation is intended to be a transition; she will remain with the company until August 14, 2024.
- The company has officially initiated a search for a new Chief Financial Officer.
- The filing explicitly states the resignation is not due to disagreements regarding financials, operations, policies, or practices.
Tenaya Therapeutics announced the voluntary resignation of Jin-Long Chen from the Board of Directors and the Corporate Governance & Nominating Committee, effective June 25, 2024.
📋 Key Facts
- Jin-Long Chen resigned as a director on June 25, 2024.
- Resignation includes his role on the Corporate Governance & Nominating Committee.
- The resignation was voluntary and not due to any disagreement with the Company or its Board.
Tenaya Therapeutics held its annual meeting of stockholders on May 30, 2024. The filing reports the successful election of three Class III Directors and the ratification of Deloitte & Touche LLP as the company's independent auditor for fiscal year 2024.
📋 Key Facts
- Annual Meeting held on May 30, 2024.
- Faraz Ali, M.B.A., June Lee, M.D., and Deepak Srivastava, M.D. were elected to the Board of Directors until the 2027 annual meeting.
- Stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.
Tenaya Therapeutics announced a workforce reduction affecting approximately 22% of its employees as part of cost containment measures. The company expects to incur $1.3 million to $1.5 million in severance and benefit charges, primarily recognized in Q2 2024.
🚩 Red Flags
- Significant workforce reduction (22%) often indicates a need to preserve cash runway in clinical-stage biotech companies.
- Forward-looking statements highlight risks regarding the ability to raise additional funding required for product development.
📋 Key Facts
- Workforce reduction announced on May 14, 2024; employees notified on May 13, 2024.
- The reduction impacts approximately 22% of the total workforce.
- Estimated costs for the workforce reduction are between $1.3 million and $1.5 million.
- Costs primarily relate to cash severance and continuing health benefits.
- Financial results for the quarter ended March 31, 2024 were released simultaneously via press release.
Tenaya Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended December 31, 2023.
📋 Key Facts
- Report date: March 18, 2024
- Reporting period: Quarter ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Company is classified as an emerging growth company.
Tenaya Therapeutics announced a registered direct offering of common stock and pre-funded warrants to raise approximately $50 million in gross proceeds. The offering is priced at $4.50 per share for common stock and $4.499 per underlying share for the warrants.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of over 8.8 million new shares and warrants.
- Use of pre-funded warrants often indicates a desire to avoid immediate ownership threshold triggers (9.99% limit mentioned).
📋 Key Facts
- Offering size: 8,888,890 shares of common stock and 2,222,271 pre-funded warrants.
- Gross proceeds expected to be approximately $50.0 million before expenses.
- Common stock offering price: $4.50 per share; Underwriter purchase price: $4.23 per share.
- Pre-funded warrant offering price: $4.499 per underlying share; Underwriter purchase price: $4.23 per underlying share.
- Warrants have an exercise price of $0.001 per share and are exercisable on or after issuance.
- Underwriters include Leerink Partners LLC and Cowen and Company, LLC.
- Expected closing date: February 12, 2024.